Physician profile
Robert M Langdon, JR.
NPI 1689654618
$899.70
in general payments reported to CMS, 2019-2025
26 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.04 · 2021: $208 · 2023: $30.65 · 2024: $184 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577 · Education: $73.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.89 |
| Education | $73.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $99.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $99.12 | 2024-2025 | Opdualag, Opdivo |
| Sanofi-Aventis U.S. LLC | $84.95 | 2021 | |
| Pfizer INC. | $75.96 | 2023-2025 | |
| Abbvie INC. | $71.00 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $61.08 | 2025 | Enjaymo, Panhematin |
| Genentech, INC. | $53.45 | 2025 | |
| Gilead Sciences, INC. | $44.61 | 2021-2025 | Trodelvy |
| Covidien LP | $41.04 | 2019 | |
| Servier Pharmaceuticals LLC | $33.65 | 2025 | |
| Exelixis INC. | $27.96 | 2024 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $27.73 | 2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $24.07 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Eisai INC. | $20.49 | 2025 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.09 | 2024 | Phesgo, Itovebi |
| Karyopharm Therapeutics INC. | $15.62 | 2025 | Xpovio |
| Caris Mpi, INC. | $15.49 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $15.26 | 2024 | Mektovi, Braftovi, Tukysa |
| Intera Oncology, INC | $13.96 | 2025 | Intera |
| Celgene Corporation | $12.95 | 2023 | Pomalyst |
| Merck Sharp & Dohme LLC | $12.77 | 2025 | Welireg, Keytruda |
| Epizyme, INC. | $11.50 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Langdon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.